Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy of Esomeprazole 40 mg Once Daily Versus Placebo or Esomeprazole 20 mg Once Daily Versus Placebo in Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs

NCT00241553 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00241553
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00241553 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy of Esomeprazole 40 mg Once Daily Versus Placebo or Esomeprazole 20 mg Once Daily Versus Placebo in Prevention of Upper Gastrointestinal Symptoms Associated With Continuous Use of NSAIDs Including COX-2 Selective NSAIDs
Lead sponsor
AstraZeneca
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2001
Completion date
February 28, 2003
Enrollment
276
Sites
136

Conditions

As the registry lists them; a condition with its own page is linked.

nsaids, upper gi symptoms